Prevalence of metabolic syndrome and associated factors among psychiatric patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia

Nigist Alemayehu Woldekidan¹*, Ammas Siraj Mohammed², Amsalu Degu³, Yohannes Tadiwos⁴

¹ Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia, ² Department of Clinical Pharmacy, School of Pharmacy, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia, ³ School of Pharmacy and Health Sciences, United States International University Africa, Nairobi, Kenya, ⁴ Department of Pharmacology, School of Pharmacy, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia

* Ngstalem14@gmail.com, Nigest.Alemayehu@uog.edu.et

Abstract

Background
Psychiatric patients are at increased risk of being overweight or obese, and subsequently develop metabolic syndrome. Nevertheless, data regarding associated factors for weight gain are limited and inconsistent.

Objective
The present study aimed to determine the risk of metabolic syndrome and its associated factors among psychiatric patients.

Method
A cross-sectional quantitative study was conducted among all psychiatric patients at the Psychiatric Unit of the University of Gondar Comprehensive Specialized Hospital from March 1- April 1, 2018. All eligible psychiatric patients were interviewed about their socio-demographic status, and clinical characteristics and useful parameters for the study were recorded from the medical records of the patients and by measuring waist to height ratio. Descriptive statistics were used to summarize baseline information. Binary logistic regression was used to determine the associated factors and P-value <0.05 and confidence interval (CI) of 95% were used as cut off points for determining statistical significance.

Result
From 300 patients included in the study, 168(56%) patients were females, and around 50.3% of the study participants had low literacy levels. As per waist to a height ratio scale, 58% (174) of the patients had a risk of metabolic syndrome. The Binary logistic regression analysis indicated that sex (p< 0.0001), occupation (p= 0.032), marital status (p= 0.006), and...
distance from the hospital (p<0.0001) were statistically significant determinants of metabolic syndrome risk in the psychiatric patient in our setting.

Conclusion
The majority of the psychiatric patients in the study setting had a risk of metabolic syndrome. Sex, marital status, employment status, and distance to the hospital were significantly associated with metabolic syndrome. Routine physical and laboratory investigations to detect metabolic syndrome are indispensable in psychiatric patients to prevent cardiovascular complications.

Background
Metabolic Syndrome (Mets) is a worldwide health problem that can be defined as a constellation of risk factors including glucose intolerance, raised blood pressure, obesity, and dyslipidemia, which increases cardiovascular morbidity and mortality rate [1]. During the last two decades, the frequency of obesity and diabetes mellitus has increased in the United States, which is directly associated with cardiovascular disease (CVD) [2]. When compared to people without MetS, the chance of heart attack or stroke is three times more and the chance of death because of cardiovascular complication is twice higher in MetS patients [3].

In contrast to the general population, patients with schizophrenia have a higher rate of Mets [4]. As a result of this, these patients are at increased risk of premature CVD and subsequent shorter life expectancy [5–7]. A previous study showed that 31–34% of the population with severe and persistent psychiatric disorders complicated by MetS died from CVD, which indicates how much Mets directly increases the risk of developing CVD [8].

Abnormally large waist circumference (WC) has been debated in the literature as a controversial measurement parameter for the assessment of metabolic Mets. It was not consistently considered as a diagnostic criterion for determining Mets [9]. However, increased WC is the main feature of Mets, and it is associated with high fasting blood glucose (FBG) and hypertension as well as lipid dysregulation. Other metabolic risk factors include central obesity and insulin resistance [10,11]. The waist height ratio (WhtR) has been recommended as a simple cost, and noninvasive screening tool for psychiatric patients receiving antipsychotic medications to assist in identifying metabolic screening [12]. Although Mets in psychiatric patients is a burning issue causing CVD, the screening guidelines are still not widely applied, even in developed countries [13,14]. Besides, the studies conducted regarding Mets risk show inconsistent results. Therefore, the present study was aimed to determine the risk of Mets and its associated factors among psychiatric patients in the study setting, since limited data is available in the current study area regarding metabolic risk and associated factors.

Methods
Study design, setting and period
A cross-sectional study was conducted among inpatient and outpatient psychiatric patients attending the University of Gondar Comprehensive Specialized Hospital (UOGCSH). UOGCSH is one of the oldest teaching hospitals in the country, located in Gondar town, and it is 738km northwest of the capital city Addis Ababa, Ethiopia. The study was conducted from March 1- April- 30, 2018.
Inclusion and exclusion criteria
All patients aged 18 years and above who received treatment for at least six months from the inpatient or outpatient psychiatry clinic and who attended the clinic during the study period were included in the study. Nonetheless, unstable psychiatric patients were excluded from the study due to the inability to interview and measure the required metabolic parameters of the patients.

Sample size determination
All eligible psychiatric patients who fulfilled the inclusion criteria and who received treatment in the inpatient and outpatient Psychiatric departments during the study period were included as the study sample.

Study variables
The independent variable includes age, gender, religion, ethnicity, education status, occupation, marital status, area of residence, distance from the hospital, and monthly income. In contrast, the dependent variable is the Mets risk.

Data collection and management
The data collection was performed by two well-trained psychiatric nurses who were working at the psychiatry clinic in UOGCSH, and, who have professional experience in approaching and drawing necessary information from psychiatric patients. Necessary training was provided by principal investigator to data collectors on contents of the questionnaire, the data collection methods and ethical concerns. The data was collected through face-to-face interviews and hospital files of the patients using data collection instruments and measuring essential parameters from the patients. The data collection instrument was adapted from the previous studies [12,15,16], and it includes sections focusing on socio-demographic, other baseline characteristics, and clinical characteristics. WhtR was calculated by dividing waist circumference (in inches) by height (in inches). Waist circumference was measured midway between the inferior costal margin and the superior border of the iliac crest at the end of normal expiration in a standing position. While height was determined using the wall-mounted measuring tape in the ward, and the participants were not wearing shoes. The WhtR parameter of over 0.50 was considered at risk of Mets [12].

Data quality assurance
The data collection instrument was also pretested on fifteen patients who were not included in the final analysis, and then it was validated and pertinent modifications were made before the beginning of actual data collection. Data collectors were trained well on the measurement of waist circumference and height to make the result consistent throughout the collectors. The investigators were also trained on ways of approaching the patients and upkeep their permission for an interview before the data collection process.

Data analysis
The collected data were entered and analyzed using Statistical packages for Social Sciences (SPSS) version 20 statistical software. Frequencies and percentages were used to describe socio-demographic and other characteristics, and binary logistic regression was done to determine the association among variables. P-value <0.05 and 95% confidence interval (CI) were used as cut points for determining statistical significance.
Ethical consideration

Ethical clearance was obtained from the Research and Ethics Review Committee, School of Pharmacy, University of Gondar. Then, permission to collect data from patients was obtained from the Clinical Directorate of UOGCSH. Names and other personal identifications were eliminated during data collection to ensure the confidentiality of the information collected. Written informed consent and oral explanations about the purpose of the study were provided to all the participants during data collection and participation was voluntary based. The capacity to participate was determined by asking the participants understanding of the purpose of the study.

Result

A total of 300 patients were interviewed, of which 168 (56%) were females, and most of them 145 (48.3%) were in the age group 18–30 years (Mean age 31.97). Half (151, 50.3%) of the participants had low literacy levels and were self-employed (156, 52%). Nearly half of them live in rural areas 167(55.7%) and more than two-third of participants are from ≤ 40km distance (220, 73.3%).

The present study showed that schizophrenia (147, 49%) was the most commonly diagnosed psychiatric disorder in the study setting. Major depression (100, 33.3%) was the second leading case diagnosed in this setting. On the other hand, brief psychosis and generalized anxiety disorders were the least common psychiatric disorders in our setting. The majority of the study participants (138, 46%) had ≤ five years of duration of illness, and 95% of the patients had been treated with pharmacotherapy for a period of fewer or equal to ten years. Besides, haloperidol was the most commonly prescribed antipsychotic in the study setting (Table 1). As per waist to a height ratio scale, 58% (174) of the patients had a risk of metabolic syndrome.

In the binary logistic regression analysis, the study indicated that male patients had an 88% decreased risk of Metsas compared to female patients (AOR = 0.191, 95% CI = 0.093–0.391, p<0.0001). Besides, participants who were government workers (AOR = 1.009, 95% CI = 0.168–6.052, p = 0.032) and self-employed (AOR = 0.339, 95% CI = 0.143–0.802, p = 0.032) were 1.009 and 0.339 times less likely to develop risk of Metsas compared to unemployed patients, respectively. The current study also showed that being single had a 73% decreased risk of acquiring Mets in contrast to married patients (AOR = 0.270, 95% CI = 0.107–0.684, p = 0.006). On the other hand, patients who were living closer to the hospital had a higher chance of getting Mets. However, the other parameters did not show a statistically significant association with the Mets risk (Table 2).

Discussion

Based on WhtR value over 0.50 as a parameter that reveals confirmation of abdominal obesity, 58% of participants had abdominal obesity, which directly indicates Metsrisk. One factor that could lead to such increased metabolic risk is the duration of the illness, with more than half (54%) of the patients having a duration of illness greater than 5 years. There is some evidence for a dose-response association with the severity and duration of symptoms and for a bidirectional longitudinal impact between psychiatric disorders and Mets. Associations generally seem stronger with abdominal obesity and dyslipidemia dysregulation than with hypertension. Contributing mechanisms are an unhealthy life style and a poor adherence to medical regimen which are prevalent among psychiatric patients. Specific psychiatric medications have also shown a profound impact in increasing Mets dysregulations. Finally, pleiotropy in genetic vulnerability and pathophysiological mechanisms, such as those leading to the increased central
Table 1. Socio-demographic characteristics and clinical features of participants.

| Variable                        | Category                 | N   | Percentage % |
|---------------------------------|--------------------------|-----|--------------|
| **Age**                         | 18–30                    | 145 | 48.3         |
|                                 | 31–40                    | 100 | 33.3         |
|                                 | 41–50                    | 38  | 12.7         |
|                                 | 51–60                    | 17  | 5.7          |
| **Sex**                         | Male                     | 132 | 44           |
|                                 | Female                   | 168 | 56           |
| **Religion**                    | Orthodox                 | 237 | 79           |
|                                 | Muslim                   | 67  | 20.3         |
|                                 | Protestant               | 2   | 7            |
| **Ethnicity**                   | Amhara                   | 293 | 97.7         |
|                                 | Tigray                   | 7   | 2.3          |
| **Education Status**            | Unable to read and write | 151 | 50.3         |
|                                 | Primary school (1–8)     | 56  | 18.7         |
|                                 | Secondary school (9–10)  | 56  | 18.7         |
|                                 | Tertiary school          | 37  | 12.3         |
| **Occupation**                  | Government employed      | 16  | 5.3          |
|                                 | Self- employed           | 156 | 52           |
|                                 | Unemployed               | 128 | 42.7         |
| **Marital Status**              | Single                   | 107 | 35.7         |
|                                 | Married                  | 193 | 64.3         |
| **Area of Residence**           | Urban                    | 133 | 44.3         |
|                                 | Rural                    | 167 | 55.7         |
| **Monthly income in ETB**       | < 500                    | 214 | 71.3         |
|                                 | 500–1499                 | 66  | 22           |
|                                 | 1500–2499                | 11  | 3.7          |
|                                 | > 2500                   | 9   | 3            |
| **Distance from the hospital (in km)** | < 40km              | 220 | 73.3         |
|                                 | > 40                     | 80  | 26.7         |
| **Type of mental illness**      | Schizophrenia            | 147 | 49           |
|                                 | Major depression         | 100 | 33.3         |
|                                 | Bipolar disorder         | 26  | 8.7          |
|                                 | Generalized Anxiety      | 13  | 4.3          |
|                                 | Brief Psychosis          | 14  | 4.7          |
| **Duration of Illness**         | < 5 year                 | 138 | 46           |
|                                 | 6–10 year                | 116 | 38.7         |
|                                 | 11–15 year               | 30  | 10           |
|                                 | 16–20 year               | 7   | 2.3          |
|                                 | > 21 years               | 9   | 3            |
| **Years of Pharmacotherapy**   | ≤ 10 years               | 285 | 95           |
|                                 | > 10 years               | 15  | 5.0          |
| **Drug prescribed**             | Haloperidol              | 92  | 30.7         |
|                                 | Chlorpromazine           | 79  | 26.3         |
|                                 | Chlorpromazine with amitriptyline | 25 | 8.3 |
|                                 | Fluoxetine               | 55  | 18.3         |
|                                 | Carbamazepine            | 7   | 2.3          |
|                                 | Risperidone              | 15  | 5            |
|                                 | Amitriptyline            | 27  | 9            |

(Continued)
and peripherial activation of immunometabolic or endocrine symptoms, plays in both Mets and psychiatric disorder development [17].

Previous studies showed that the risk of Mets was prevalent among patients on second-generation antipsychotics [18,19]. However, in our setting due to the limited availability of second-generation antipsychotics, first-generation antipsychotics such as haloperidol was frequently prescribed. Hence, the lack of a significant association between Mets risk and the prescribed medications in our setting could be probably due to the prevalent use of first-generation antipsychotics which has a lower risk of Mets. Related to the specific case, it has been reported that the prevalence of Mets in patients with major depression ranges from 36–50% [16]. Nevertheless, there was no significant association identified between Mets and the types of psychiatric disorders in our setting. The finding of the study indicated that females had an increased risk than males which is in line with a study conducted in South Africa [20] and Brazil [21], the study done in jimma University Specialized Hospital, Southeast Ethiopia also showed a significant association of Mets with being female [22]. Another study also showed that the prevalence rate of Mets was 51.6–54.2% in women and 36–36.6% in male [23]. This increased risk in women might be because of difference in body composition, with women having more fat mass. Different conditions such as pregnancy, oral contraceptive therapy, and menopause could also contribute to Mets [24].

Significant association between employment status and Mets risk was shown in our study. A previous study showed that there is a relationship between employment status and physical inactivity, which was explained mainly by health-related and socioeconomic factors [25]. Another study also revealed that there was an association between physical inactivity and Mets [26]. A significant association in the current study could also be because of the higher unemployment, which leads to stress imposes peoples to be stressed and stress is thought to influence eating behavior. Stress is more likely to increase food intake, along with high consumption of palatable food, rich in saturated fat and sugar [27].

Our study also revealed that those who were single have an increased risk for Mets than married/ever married. Similarly, a study conducted in this area showed that marital status to be of important factor. Here, living single was to be associated with a poorer lifestyle and higher CVD risk, at least in males [28]. Another study also reported marital quality as one of the important factors that mediate the association between marital status and Mets [29].

Furthermore, participants who were relatively near to the hospital were at risk of Mets than those far away. The possible reason could be as the hospital is in an urban area, the majority of the study population (73.3%) are living near the hospital, having a sedentary life and eating an unhealthy diet. However, an insignificant association was found between living in the urban area (44.3% of the patients) and Mets. This could be because even though the patients are residing in the rural areas, the distance from their home to the hospital might be lesser than 40 km as is evident by the result which shows that 73.3% of the participants are living near the hospital at a distance of less than 40 km.

Psychiatric patients are at increased risk of Mets and this risk is present for a range of psychiatric conditions, including major depressive disorder, bipolar disorder, schizophrenia, anxiety disorder, attention-deficit/hyperactivity disorder, and posttraumatic stress disorder [17].
| Variable                  | Category     | COR (95%CI)        | AOR (95%CI)       | p-value |
|---------------------------|--------------|--------------------|-------------------|---------|
| Age                       | 18–30        | 0.682[0.228–2.040] | 1.315[0.188–9.169]| 0.984   |
|                           | 31–40        | 0.741[0.242–2.271] | 1.128[0.171–7.422]|         |
|                           | 41–50        | 0.639[0.187–2.185] | 1.114[0.151–8.213]|         |
|                           | 51–60        | 1                   | 1                 |         |
| Sex                       | Male         | 0.207[0.127–0.343] | 0.191[0.093–0.391]| <0.0001**|
|                           | Female       | 1                   | 1                 |         |
| Ethnicity                 | Amhara       | 1.285[0.282–5.849] | 0.472[0.061–3.628]| 0.471   |
|                           | Tigray       | 1                   | 1                 |         |
| Education Status          | Unable to read and write | 1.033[0.492–2.168] | 2.350[0.655–8.433]| 0.325   |
|                           | Primary School (1–8) | 1.522[0.630–3.675] | 2.759[0.665–11.448]|         |
|                           | Secondary School (9–10) | 0.755[0.323–1.762] | 1.225[0.352–4.260]|         |
|                           | Tertiary School | 1                   | 1                 |         |
| Occupation                | Government employed | 0.377[0.129–1.099] | 1.009[0.168–6.052]| 0.032*  |
|                           | Self-employed | 0.316[0.188–0.532] | 0.339[0.143–0.802]|         |
|                           | Unemployed   | 1                   | 1                 |         |
| Marital Status            | Single       | 0.633[0.390–1.029] | 0.270[0.107–0.684]| 0.006*  |
|                           | Married      | 1                   | 1                 |         |
| Area of Residence         | Urban        | 1.438[0.892–2.316] | 0.696[0.335–1.445]| 0.331   |
|                           | Rural        | 1                   | 1                 |         |
| Monthly income in ETB     | <500         | 2.627[0.684–10.889] | 1.540[0.199–11.947]| 0.269   |
|                           | 500–1499     | 1.411[0.348–5.728] | 0.596[0.083–4.280]|         |
|                           | 1500–2499    | 1.042[0.177–6.123] | 1.267[0.089–17.942]|         |
|                           | >2500        | 1                   | 1                 |         |
| Distance to the hospital(in km) | ≤40km | 3.000[1.770–5.084] | 4.530[2.002–10.252]| <0.001**|
|                           | >40km        | 1                   | 1                 |         |
| Type of mental illness    | Schizophrenia | 0.188[0.041–0.871] | 0.737[0.103–5.273]| 0.196   |
|                           | Major depression | 0.500[0.105–2.389] | 3.536[0.154–81.167]|         |
|                           | Bipolar disorder | 0.267[0.049–1.449] | 3.203[0.298–34.363]|         |
|                           | Generalized Anxiety | 0.267[0.041–1.727] | 3.705[0.105–130.891]|         |
|                           | Brief Psychosis | 1                   | 1                 |         |
| Duration of Illness       | <5 year      | 0.458[0.092–2.289] | 1.196[0.051–28.266]| 0.609   |
|                           | 6–10 year    | 0.564[0.112–2.845] | 1.071[0.049–25.436]|         |
|                           | 11–15 year   | 0.374[0.066–2.106] | 0.723[0.036–14.469]|         |
|                           | 15–20 year   | 0.214[0.024–1.877] | 0.147[0.005–4.234]|         |
|                           | >21 years    | 1                   | 1                 |         |
| Years of Pharmacotherapy  | ≤ 10 years   | 0.844[0.281–2.537] | 0.323[0.030–3.422]|         |
|                           | >10 years    | 1                   | 1                 |         |
| Drug indicated            | Haloperidol  | 0.159[0.051–0.491] | 0.212[0.014–3.320]| 0.099   |
|                           | Chlorpromazine | 0.376[0.117–1.202] | 0.625[0.039–10.051]|         |
|                           | Chlorpromazine with amitriptyline | 0.913[0.202–4.120] | 0.740[0.113–4.858]|         |
|                           | Fluoxetine   | 0.304[0.092–1.006] | 0.338[0.066–1.734]|         |
|                           | Carbamazepine | 0.130[0.021–0.817] | 0.070[0.002–2.149]|         |
|                           | Risperidone  | 0.261[0.059–1.148] | 0.088[0.002–4.162]|         |
|                           | Amitriptyline | 1                   | 1                 |         |

(Continued)
In the current study, no correlation was found between the type of psychiatric disorder and the risk of Mets. One possible reason might be the prolonged duration of the mental disorder that is observed in the majority of the study participants (54%), increasing the chance of metabolic disorder irrespective of the type of the type of psychiatric disorder.

**Limitation of the study**

Identifying patients with Mets and other comorbid conditions with the help of laboratory parameters in the psychiatric care unit was not carried out in our setting. For that reason, the study was unable to differentiate patients who already have Mets. In addition to this, as it is a cross-sectional study, confounding variables cannot be controlled to identify definitive exposing factors for Mets at risk. The lack of information regarding patients’ awareness of suffering from clinical conditions associated with metabolic syndrome could also be considered as a possible limitation since adequate awareness of individual cardiovascular risk profile is a key element for improving adherence to life-style rules and adoption of preventive treatment strategies [30].

**Conclusion**

The present study showed that long-term psychiatric patients are at increased risk of Mets. Sex, marital status, employment status, and distance to the hospital were statistically associated with Mets. Therefore, routine physical and laboratory investigations to detect Mets are indispensable to prevent cardiovascular complications.

**Supporting information**

S1 File. Metabolic syndrome among psychiatric out patients.
(PDF)

**Author Contributions**

**Conceptualization:** Nigist Alemayehu Woldekidan.

**Data curation:** Nigist Alemayehu Woldekidan, Ammas Siraj Mohammed.

**Formal analysis:** Nigist Alemayehu Woldekidan.

**Funding acquisition:** Nigist Alemayehu Woldekidan, Yohannes Tadiwos.

**Investigation:** Nigist Alemayehu Woldekidan.

**Methodology:** Nigist Alemayehu Woldekidan, Ammas Siraj Mohammed, Amsalu Degu, Yohannes Tadiwos.

### Table 2. (Continued)

| Variable             | Category | COR (95%CI)      | AOR (95%CI)      | p-value |
|----------------------|----------|------------------|------------------|---------|
| Medication Cost/day  | ≤5       | 0.847[0.208–3.457] | 0.355[0.017–7.287] | 0.501   |
|                      | >5       | 1                | 1                |         |

*Significant at 0.05 levels
**significant at 0.01 levels.
COR: Crude odds ratio, AOR: Adjusted odds ratio, CI: Confidence interval, ETB: Ethiopian Birr.

https://doi.org/10.1371/journal.pone.0256195.1002
Project administration: Nigist Alemayehu Woldekidan, Ammas Siraj Mohammed, Amsalu Degu, Yohannes Tadiwos.

Resources: Nigist Alemayehu Woldekidan, Ammas Siraj Mohammed, Amsalu Degu, Yohannes Tadiwos.

Software: Nigist Alemayehu Woldekidan, Ammas Siraj Mohammed, Amsalu Degu, Yohannes Tadiwos.

Supervision: Nigist Alemayehu Woldekidan, Amsalu Degu, Yohannes Tadiwos.

Validation: Nigist Alemayehu Woldekidan, Ammas Siraj Mohammed, Amsalu Degu, Yohannes Tadiwos.

Visualization: Nigist Alemayehu Woldekidan, Ammas Siraj Mohammed, Yohannes Tadiwos.

Writing – original draft: Nigist Alemayehu Woldekidan.

Writing – review & editing: Nigist Alemayehu Woldekidan, Ammas Siraj Mohammed, Amsalu Degu, Yohannes Tadiwos.

References

1. Yates K.F., Sweat V., Yau P.L., Turchiano M.M., and Convit A., 2012. Impact of metabolic syndrome on cognition and brain: A selected review of the literature. ArteriosclerosisVasc. Biol., 32: 2060–2067. https://doi.org/10.1161/ATVBAHA.112.252759 PMID: 22895667

2. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Jama. 2003; 289(1):76–9. https://doi.org/10.1001/ jama.289.1.76 PMID: 12503980

3. Isomaa B, Almgren P, Tuomilehto J, Forsen B, Lahtikari K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24(4):683–9. https://doi.org/10.2337/ diacare.24.4.683 PMID: 11315831

4. Arango C, Bobes J, Aranda P, Garcia-Garcia R, Rejas J. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophrenia research. 2008; 104(1–3):1–12. https://doi.org/10.1016/j.schres.2008.05.009 PMID: 18606526

5. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophrenia research. 2010; 119(1–3):101–9. https://doi.org/10.1016/j.schres.2010.02.1030 PMID: 20219322

6. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophrenia research. 2011; 131(1–3):101–4. https://doi.org/10.1016/j.schres.2011.06.008 PMID: 21741216

7. Wahlbeck K, Westman J, Nordentoft M, Gissler M, Laursen TM. Outcomes of Nordic mental health systems: the life expectancy of patients with mental disorders. The British journal of psychiatry: the journal of mental science. 2011; 199(6):453–8. https://doi.org/10.1192/bjp.bp.110.085100 PMID: 21593516

8. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie. 2006; 51(8):492–501. https://doi.org/10.1177/070674370605100804 PMID: 16933586

9. Citrome L, Holt RJ, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clinical drug investigation. 2011; 31(7):455–82. https://doi.org/10.2165/11589060-000000000-00000 PMID: 21495734

10. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K; DECODE Insulin Study Group. Plasma insulin and cardiovascular mortality in nondiabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia2004; 47: 1245. https://doi.org/10.1007/s00125-004-1433-4 PMID: 15241592

11. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004; 53(8):2087–94. https://doi.org/10.2337/diabetes.53.8.2087 PMID: 15277390
12. Martha C, Margaret K, Geoffrey P-M, Emily C, Devan H. A simple screening tool for metabolic syndrome risk in the psychiatric patient treated with antipsychotic medication. Sciedu Press. 2015; 3(2):115–24.

13. Holt RI, Abdelrahman T, Hirsch M, Dhesi Z, George T, Bincooe T, et al. The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. Journal of psychopharmacology (Oxford, England). 2010; 24(6):867–73. https://doi.org/10.1177/0269881109102788 PMID: 19304866

14. Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. The Medical Journal of Australia. 2009; 190(4):185–9. https://doi.org/10.5694/j.1326-5377.2009.tb02344.x PMID: 19220182

15. Carville Patch M, Knight M, Phillips-McEnany G, Chavas E, Hawkins D. A simple screening tool for metabolic syndrome risk in the psychiatric patient treated with antipsychotic medication. Clinical Nursing Studies. 2015; 3(2).

16. Takeaki T, Mutsuh iro N, Kyoko N, Mariko I, Shinobu T, Yasuko S, et al. Association of the metabolic syndrome with depression and anxiety in Japanese men: A 1-year cohort study. Diabetes Metab Res Rev. 2009; 25:762–7. https://doi.org/10.1002/dmrr.1041 PMID: 19389027

17. Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018; 20(1):63–73. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. https://doi.org/10.31887/DCNS.2018.20.1/bpenninx PMID: 29946213

18. Rahman A, Asmara H, Baharudin A, Sidi H. Metabolic syndrome in psychiatric patients with primary psychotic and mood disorders. Asean J Psychiatry. 2008; 10.

19. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. The Journal of clinical psychiatry. 2007; 68 Suppl 4:8–13. PMID: 17539694

20. Maaroganye K, Mohapi M, Kruger C, Rheeder P. The prevalence of metabolic syndrome and its associated factors in long-term patients in a specialist psychiatric hospital in South Africa. African journal of psychiatry. 2013; 16(6).

21. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Revista brasileira de psiquiatria (Sao Paulo, Brazil: 1999). 2007; 29(4):330–6. https://doi.org/10.1590/s1516-44662007000400007 PMID: 18200397

22. Asaye S, Bekele S, Tolessa D, Cheneke W. Metabolic syndrome and associated factors among psychiatric patients in Jimma University Specialized Hospital, South West Ethiopia. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2018; xxx; xxx-xxx.

23. Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. The American journal of psychiatry. 2013; 170(3):265–74. https://doi.org/10.1176/appi.ajp.2012.12050620 PMID: 23361837

24. Bentley-Lewis R, Koruda K, Seely EW. The metabolic syndrome in women. Nature clinical practice Endocrinology & metabolism. 2007; 3(10):696–704. https://doi.org/10.1038/ncpemet0616 PMID: 17893688

25. Macassa G, Ahmadi N, Alfredsson J, Barros H, Soares J, Stankunas M. Employment status and differences in physical activity behavior during times of economic hardship: results of a population-based study. International Journal of Medical Science and Public Health. 2016; 5(1):102.

26. Walther S, Stegmayer K, Horn H, Razavi N, Müller TJ, Strik W. Physical Activity in Schizophrenia is Higher in the First Episode than in Subsequent Ones. Frontiers in Psychiatry. 2014; 5:191. https://doi.org/10.3389/fpsyt.2014.00191 PMID: 25601842

27. Galling B, Garcia MA, Osuchukwu U, Hagi K, Correll CU. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opinion on Drug Safety. 2015; 14(8):1181–99. https://doi.org/10.1517/14740338.2015.1053457 PMID: 26107820

28. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia research. 2005; 80(1):19–32. https://doi.org/10.1016/j.schres.2005.07.014 PMID: 16137860

29. Troxel WM, Matthews KA, Gallo LC, Kuller LH. Marital quality and occurrence of the metabolic syndrome in women. Archives of Internal Medicine. 2005; 165(9):1022–1027. https://doi.org/10.1001/archinte.165.9.1022 PMID: 15883241

30. Cicero AFG, Fogacci F, Tocci G, Ventura F, Presta V, Grandi E, et al. Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. 2020. 30: 907–914. https://doi.org/10.1016/j.numecd.2020.03.005 PMID: 32249143